Myomo (NYSEAMERICAN:MYO – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02), FiscalAI reports. Myomo had a negative net margin of 33.53% and a negative return on equity of 138.85%. The firm had revenue of $12.33 million for the quarter, compared to analyst estimates of $11.51 million.
Myomo Trading Up 15.7%
NYSEAMERICAN MYO traded up $0.19 during mid-day trading on Monday, reaching $1.40. 348,763 shares of the stock were exchanged, compared to its average volume of 536,113. The stock has a 50 day simple moving average of $1.38 and a 200-day simple moving average of $1.09. Myomo has a one year low of $0.60 and a one year high of $1.89. The company has a debt-to-equity ratio of 1.98, a current ratio of 2.31 and a quick ratio of 2.01. The stock has a market cap of $55.45 million, a P/E ratio of -4.12 and a beta of 1.74.
Insider Activity
In other news, insider Harry Kovelman sold 17,250 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $1.73, for a total transaction of $29,842.50. Following the completion of the sale, the insider owned 105,983 shares of the company’s stock, valued at $183,350.59. This trade represents a 14.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders sold 47,738 shares of company stock worth $70,662. 12.14% of the stock is currently owned by corporate insiders.
Myomo Company Profile
Myomo, Inc is a medical device company that develops and markets wearable robotic braces designed to help individuals with impaired upper-limb function regain movement and perform activities of daily living. Its principal product is the MyoPro, a lightweight, electrically powered orthosis that detects a user’s residual muscle signals and assists movement of the arm and hand.
The MyoPro is intended for people affected by neuromuscular disorders and injuries, including stroke, brachial plexus injury, multiple sclerosis, traumatic brain injury and spinal cord injury.
Featured Articles
- Five stocks we like better than Myomo
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.
